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Abstract
Autism is a neurodevelopmental disorder characterized by deficits in verbal communication, social interactions, and the
presence of repetitive, stereotyped and compulsive behaviors. Excessive early brain growth is found commonly in some
patients and may contribute to disease phenotype. Reports of increased levels of brain-derived neurotrophic factor (BDNF)
and other neurotrophic-like factors in autistic neonates suggest that enhanced anabolic activity in CNS mediates this
overgrowth effect. We have shown previously that in a subset of patients with severe autism and aggression, plasma levels
of the secreted amyloid-b (Ab) precursor protein-alpha form (sAPPa) were significantly elevated relative to controls and
patients with mild-to-moderate autism. Here we further tested the hypothesis that levels of sAPPa and sAPPb (proteolytic
cleavage products of APP by a- and b-secretase, respectively) are deranged in autism and may contribute to an anabolic
environment leading to brain overgrowth. We measured plasma levels of sAPPa, sAPPb,A b peptides and BDNF by
corresponding ELISA in a well characterized set of subjects. We included for analysis 18 control, 6 mild-to-moderate, and 15
severely autistic patient plasma samples. We have observed that sAPPa levels are increased and BDNF levels decreased in
the plasma of patients with severe autism as compared to controls. Further, we show that Ab1-40, Ab1-42, and sAPPb levels
are significantly decreased in the plasma of patients with severe autism. These findings do not extend to patients with mild-
to-moderate autism, providing a biochemical correlate of phenotypic severity. Taken together, this study provides evidence
that sAPPa levels are generally elevated in severe autism and suggests that these patients may have aberrant non-
amyloidogenic processing of APP.
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Introduction
Autism, which is a neurodevelopmental disorder, is mostly
characterized by deficits in verbal communication, impairment in
social interactions, and the presence of repetitive, stereotyped, and
compulsive behaviors. [1]. First described by Kanner in 1943 [2],
the prevalence of the disorder has increased in recent years to near
1 in 110 [3,4,5], likely a combination of increased social
awareness, broader disease classification, and true increase in
disorder prevalence. Unfortunately, the neurobiological basis of
the disorder is at present very poorly understood. Behavioral
phenotypes exhibit very high heterogeneity, which has led to the
concept of the autism spectrum. Studies of twins show high autism
spectrum concordance between monozygotic twins (60–90%) and
very low concordance between dizygotic twins (10%), stressing the
significant heritable basis of the disorder [6]. Syndromes with
increased prevalence of autism (i.e. Fragile X syndrome, Rett
syndrome) and rare mutations linked to the disorder have
highlighted the contribution of synaptic dysfunction to disorder
etiology [7].
A widely replicated finding made by both head circumference
measurements and volumetric MRI is the presence of macrocephaly in
a proportion of autistic patients (15–30%), with up to 90%
demonstrating some degree of brain overgrowth in early years
[8,9,10,11]. This trajectory of early brain overgrowth has also been
established in at least one longitudinal study [12]. The exact nature of
this overgrowth is not quite clear, as expected increases in neuronal and
synaptic densities were not found when autistic brains were analyzed
by N-acetylaspartate magnetic resonance spectroscopy. Instead
reduced neuronal and synaptic densities were found [13]. However,
studies have found increased levels of brain-derived neurotrophic factor
(BDNF)and other neurotrophicfactorsin the blood of autisticneonates
and adults [14,15,16], suggesting that enhanced anabolic activity in the
CNS may mediate this overgrowth effect.
In this context, we previously assayed the peripheral levels of the
secreted alpha-secretase product of the amyloid-b precursor protein
(APP),orsAPPa,inautisticand controlsamples[17].APPisa type I
transmembrane protein that undergoes proteolytic processing by
secretase enzymes to liberate soluble fragments. APP expression is
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The APP promoter has a complex structure containing many
proximal and distal regulatory elements that mediate constitutive
and stimulated regulatory activities [18,19,20,21,22,23]. Regulatory
elements in the 59UTR can independently drive promoter activity,
such as a reported CAGA box [24]. Regulatory elements in the
59UTR may also post-transcriptionally regulate APP expression.
Examples include an iron responsive element [25] and IL-1
responsive element [26] involved in regulating stimulated transla-
tion of the APP transcript. The APP 39UTR also mediates post-
transcriptional regulation through several stability control elements
that regulate APP mRNA stability [27,28,29]. MicroRNA sites in
the 39-UTR also regulate APP expression, with miR-101 mediating
a very potent inhibitory effect on translation [30,31]. Once
expressed, APP is sequentially cleaved by b-secretase (BACE1)
and the c-secretase complex, releasing sAPPb and amyloid-b (Ab)
peptide, the major component of amyloid plaques found in
Alzheimer’s disease [32]. Ab is liberated from APP in two
predominant forms: the more abundant 40 amino acid form
(Ab1-40) and the less abundant, more fibrillogenic, 42 amino acid
form (Ab1-42). Alternative cleavage of APP by a-secretase and c-
secretase releases the non-amyloidogenic 3kDa peptide (p3 peptide)
and sAPPa, instead of intact 4 kDa Ab and sAPPb [32,33]. sAPPc
may be released if APP is cleaved by the c-secretase complex at the
C-terminus of the Ab domain prior to a-o rb-secretase cleavage.
The various forms of sAPP are distinguished by the length of Ab
domaincontainedattheC-terminalend:sAPPccontainsthefullAb
domain, sAPPa contains only residues 1–6 of Ab, and sAPPb
completely lacks the Ab sequence. These three sAPP species
primarily constitute the pool of total sAPP in the human plasma as
mentioned subsequently in the text. Notably, sAPPa has been well
characterized and previously found to exhibit a wide array of
neurotrophic activities [34,35] that might be important for
neurodevelopment. Further, sAPPa has been shown to stimulate
the transdifferentiation of adult bone marrow progenitor cells
(MAPCs) to neuronal phenotypes [36].
We postulate that elevated levels of sAPPa could also contribute
to brain overgrowth in a pathological state. In our previous study,
we discovered that in a subset of patients with severe autism and
aggression, plasma levels of sAPPa were significantly elevated
relative to controls and patients with mild-to-moderate autism [17].
This has led us to the hypothesis that sAPPa may contribute to an
anabolic environment in the central nervous system (CNS) leading
to brain overgrowth in autism. However, one weakness of the
previous study was small sample size. Here, we extend our previous
finding of increased sAPPa levels in severe autism in a larger,
independent cohort of patients. For the first time we demonstrate
that the increase in the sAPPa level is a general finding in severe
autism that does not require an aggressive behavioral phenotype.
Further, we find that BDNF levels are decreased in the plasma of
patients with severe autism as compared to controls. Crucially, we
also report a decrease in levels of both Ab1-40 and Ab1-42 peptides
and sAPPb in severely autistic patients as compared to controls.
These results suggest that the non-amyloidogenic processing
pathway may be favored in severe autism with the implication that
increased neurotrophic sAPPa may contribute to a state of anabolic
excess promoting overgrowth in the autistic brain.
Results
Sample Demographics
Thirty-nine patients, including 34 males, were recruited for this
study using the inclusion criteria described above (Table 1).
Eighteen patients with no overt neurological or psychiatric
abnormalities served as normal controls. Six patients with
confirmed autism diagnoses were classified with mild-to-moderate
disease as specified by CARS score between 30 and 36.5. Fifteen
autistic patients were classified as severe based on CARS score of
37 or greater. Mean ages (in years 6SD) at the time of plasma
collection for controls, mild-to-moderate and severely autistic
patients were 8.1764.33, 6.1660.68, and 6.4063.04, respectively.
One-way ANOVA did not detect any statistically significant
differences in the mean age between any of the groups (F=1.316,
p=0.281). Two children with autism had epilepsy. All children
with severe autism were mentally retarded as determined by IQ
scores less than 70. Medication history and other clinical features
for most patients were non-significant.
sAPPa is Elevated in the Plasma of Severely Autistic
Patients
As a first step in characterizing the expanded set of patient
plasma samples encompassing control, mild-to-moderate, and
severely autistic patients, plasma levels of total sAPP (a and b
combined) were analyzed by Western blot using the well-
characterized monoclonal anti-N-terminus APP antibody 22C11
[45] , which detects C-terminal truncated sAPP in the absence of
full-length APP. HSA-immunosubtracted plasma samples were
used in this analysis. Total sAPP bands were densitometrically
quantified using Image J software. No significant difference was
observed between control and either category of autistic patient by
ANOVA (F=0.239, p=0.788) (Figure 1).
To determine if the primary biochemical change observed in our
previous study of autistic and control patients was also observed in
the larger patient set under study here, sAPPa levels were
specifically assayed by ELISA. Initial tests revealed that the linearity
and sensitivity of this ELISA was suboptimal due to non-specific
binding attributed to the highprotein content of unmodified human
plasma (data not shown). Therefore, all plasma samples were HSA-
immunosubtracted prior to analysis. No change was observed in the
mean levels of sAPPa between control and mild-to-moderate
autistic patients. Notably, a very distinct and statistically significant
increase in sAPPa (,20%) was observed in severely autistic patients
relative to controls following ANOVA (F=3.82, p=0.032) and
post-hoc Dunnett’s multiple comparison test (p=0.032) (Figure 2).
This confirms the finding of increased plasma sAPPa in severely
autistic patients with aggression described in our previous study but,
importantly, the results described here did not require coexisting
behavioral aggression. Therefore, elevated peripheral sAPPa
appears to be a trend observed in the broader population of
severely autistic patients. sAPPa ELISA levels were further
normalized to total sAPP Western signals (relative units) and while
there was a trend for elevated sAPPa:total sAPP ratios in severely
autistic samples (data not shown), no statistically significant
differences were observed between any groups following ANOVA
(F=2.725, p=0.079).
sAPPb is Decreased in the Plasma of Severely Autistic
Patients
To determine if the secreted APP product of amyloidogenic
processing, sAPPb, was altered in the plasma of autistic patients in
this plasma set, sAPPb levels were assayed in HSA-immunosub-
tracted plasma by a specific sandwich ELISA. Indeed, sAPPb
levels were significantly decreased (,60%) in the plasma of
severely autistic patients relative to controls (Figure 2B) as
determined by ANOVA (F=3.223, p=0.05) and post-hoc
Dunnett’s multiple comparison test (p=0.035). Ratios of
sAPPb:total sAPP were also calculated and no significant
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following ANOVA (F=1.876, p=0.168).
Ab Peptides are Decreased in the Plasma of Severely
Autistic Patients
Increased plasma sAPPa and decreased sAPPb might suggest,
among other possible explanations, that full-length APP is
preferentially processed along the non-amyloidogenic pathway in
severe autism. To test whether production of the end-product of
the amyloidogenic pathway was also affected, both Ab1-40 and
Ab1-42 plasma levels were independently assessed by ELISA.
These assays were not affected by the high protein content of
plasma. Thus, unprocessed plasma samples were used for ELISA
analysis. The level of Ab1-40 was unchanged between control and
mild-to-moderate autistic patients but was significantly decreased
(,60%) in severely autistic patients relative to controls following
ANOVA (F=4.487, p=0.018) and post-hoc Dunnett’s multiple
comparison test (p=0.031) (Figure 3A). Similarly, plasma Ab1-42
levels demonstrated no change in patients with mild-to-moderate
autism as compared to controls but a nearly significant decrease
(,50%) in severely autistic patients as compared to controls
following ANOVA (F=3.340, p=0.047) and post-hoc Dunnett’s
multiple comparison test (p=0.055) (Figure 3B). Ratios of Ab1-
40:Ab1-42 revealed no significant difference between any groups
following ANOVA (F=0.589, p=0.56) (Figure 3C).
To further characterize changes to the balance of non-
amyloidogenic and amyloidogenic APP processing products across
patient samples, levels of Ab peptides (products of amyloidogenic
processing) were normalized to levels of sAPPa (product of non-
amyloidogenic processing) as determined by ELISA. Levels of
both Ab1-40 and Ab1-42 were more significantly reduced in
severely autistic samples relative to controls following sAPPa
normalization (Figure 4), as indicated by ANOVA [(F=7.281,
p=0.002) and (F=4.875, p=0.015), respectively] and post-hoc
Dunnett’s multiple comparison test (p=0.003 and p=0.012,
respectively). This highlights the inverse nature of changes to the
secreted products of the amyloidogenic and non-amyloidogenic
pathways in the plasma of these severely autistic patients.
BDNF Protein Levels are Decreased in the Plasma of
Severely Autistic Patients
BDNF has reported links to autism and may have functional
roles similar to sAPPa. To determine if the levels of BDNF were
altered in the plasma of our patient set, unprocessed samples were
assayed by human BDNF specific ELISA. Preliminary ELISA
analyses indicated that high protein levels in unprocessed samples
did not affect sensitivity and linearity of the assay (data not shown).
Peripheral BDNF levels have been reported to change with age
Table 1. Demographic information for study participants.
Patient
No Dx CARS Age (yrs)
a Sex Ethnicity
1 Normal 15 7.7 Male Caucasian
2 Normal 15 6.0 Male Caucasian
3 Normal 15 5.3 Female Caucasian
4 Normal 15 4.8 Female Caucasian
5 Normal 15 6.5 Male Caucasian
6 Normal 15 4.2 Female Caucasian
7 Normal 15 7.7 Male Hispanic
8 Normal 15 11.8 Male Caucasian
9 Normal 15 14.7 Male Caucasian
10 Normal 15 18.3 Male Caucasian
11 Normal 18 11.3 Male Caucasian
12 Normal 15 9.6 Male Caucasian
13 Normal 15 13.6 Male Caucasian
14 Normal 15 3.8 Male Caucasian
15 Normal 15 7.5 Male Caucasian
16 Normal 15 2.7 Male Caucasian
17 Normal 15 2.8 Male Caucasian
18 Normal 15 8.9 Male Caucasian
19 Autism (M) 30 5.7 Male Caucasian
20 Autism (M) 33 7.0 Male Caucasian
21 Autism (M) 36 6.4 Male Caucasian
22 Autism (M) 30 6.5 Male Caucasian
23 Autism (M) 33 6.3 Male Caucasian
24 Autism (M) 32.5 5.1 Male Caucasian
25 Autism (S) 50 6.0 Male Caucasian
26 Autism (S) 52 5.5 Male Caucasian
27 Autism (S) 42 6.7 Male Caucasian
28 Autism (S) 57 6.4 Male Caucasian
29 Autism (S) 48 5.9 Male Caucasian
30 Autism (S) 43 5.2 Male Caucasian
31 Autism (S) 47 5.6 Male Caucasian
32 Autism (S) 37 4.7 Female Caucasian
33 Autism (S) 43 7.8 Female Caucasian
34 Autism (S) 39 7.9 Male Caucasian
35 Autism (S) 39 2.8 Male Caucasian
36 Autism (S) 40 5.9 Male Caucasian
37 Autism (S) 56 6.1 Male Caucasian
38 Autism (S) 45 3.2 Male Caucasian
39 Autism (S) 53 16.5 Male Caucasian
(M), mild-to-moderate autism; (S), severe autism; CARS, Childhood Autism
Rating Scale total scores.
aAge in years at time of blood draw.
doi:10.1371/journal.pone.0020405.t001
Figure 1. Plasma levels of total sAPP in control and autistic
patients. Plasma levels of total sAPP (a and b) were assayed by
Western blot from control and autistic patients. Autistic patients were
classified as mild-to-moderate or severe based on clinical CARS score.
Total sAPP bands were analyzed by scanning the final blot followed by
densitometry, ImageJ quantification, and normalization against b-actin
bands. Statistical significance was assessed using ANOVA. No significant
differences observed in mean total sAPP levels between control or
autistic patients.
doi:10.1371/journal.pone.0020405.g001
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the current study, patient age was somewhat variable but did not
differ significantly between groups. In order to increase the power
of analysis, we analyzed the differences in BDNF levels using an
ANCOVA model with age as a covariate, disorder classification as
a grouping variable, and plasma BDNF levels as a dependent
variable. This analysis allowed for the variation in BDNF levels
associated with disorder diagnosis to be estimated independent of
variation associated with age. Plasma BDNF levels (Figure 5A)
were found to be significantly decreased (,45%; F=3.672,
p=0.036) in severely autistic patients relative to controls following
post-hoc Sidak’s adjustment for multiple comparisons (p=0.038).
No significant differences were observed between mild-to-moder-
ate autism and controls (p=0.311) or between mild-to-moderate
and severe autism (p=0.98) as assessed by post hoc Sidak’s
correction. Comparing estimated marginal means (Figure 5B)
derived from model parameter estimates revealed that regressing
out age-associated variability enhanced the decrease in mean
plasma BDNF levels observed in severely autistic patients relative
to controls. No significant correlation was found between plasma
levels of sAPPa and BDNF as evaluated using Pearson’s
correlation coefficient (R=20.081, p=0.634).
Discussion
In the present report, we demonstrate that, in a much larger
patient cohort, sAPPa levels are increased and BDNF levels
decreased in the plasma of patients with severe autism (determined
by CARS score) as compared to controls. On the contrary, sAPPb
levels are decreased in the plasma of severely autistic patients.
Further, we present evidence for the first time that both Ab1-40
and Ab1-42 levels are significantly decreased in the plasma of
patients with severe autism relative to controls. Taken together our
results demonstrate that the non-amyloidogenic pathway may be
preferentially active in severely autistic patients. These findings
apparently do not extend to patients with mild-to-moderate
Figure 2. Plasma levels of sAPPa and sAPPb in control and autistic patients. (A) Plasma sAPPa and (B) sAPPb levels were quantified from
albumin-depleted samples of control and autistic patients by corresponding ELISA procedures. sAPPa and sAPPb quantities were normalized against
immunodepleted plasma protein concentrations. No difference was observed in the mean plasma sAPPa and sAPPb levels of mild-to-moderate cases
of autism relative to controls. Plasma sAPPa levels were significantly increased and sAPPb levels decreased in severely autistic patients relative to
controls Statistical significance assessed using ANOVA followed by post-hoc Dunnett’s t-test for multiple comparisons (*p,0.05).
doi:10.1371/journal.pone.0020405.g002
Figure 3. Plasma levels of Ab1-40 and Ab1-42 in control and autistic patients. (A) Ab1-40 levels were quantified by a specific sandwich
ELISA in plasma samples. Ab1-40 quantities were normalized against plasma protein concentrations. Statistical significance was assessed by ANOVA.
Plasma Ab1-40 levels are significantly decreased in severely autistic patients relative to controls (*p=0.031). (B) Ab1-42 levels were quantified by
ELISA in non-immunodepleted plasma samples. Absolute Ab1-42 quantities were normalized against plasma protein concentrations. Statistical
significance was assessed by ANOVA. Plasma Ab1-42 levels are significantly different among all groups as analyzed by ANOVA. Differences in levels
between severely autistic patients and normal controls are nearly significant (p=0.055). (C) Ratios of Ab1-40 and Ab1-42 were calculated. No
significant differences were observed between any groups (p=0.56).
doi:10.1371/journal.pone.0020405.g003
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However, it should be noted that the total number of mild-to-
moderate patients was quite low in this study, likely reducing
power of detecting true differences between this group and
controls.
Any putative plasma-based biomarker requires replication with
independent clinical cohorts. In this context, the present study
replicates and extends our previous work [17], which was - to our
knowledge - the first published account of abnormal levels of AD-
associated biomarkers in autistic patients, thereby providing
validation of this finding in two independent cohorts. The primary
finding from our original study is, for the most part, in agreement
with data from the current study, which uses a less restrictive
classification scheme whereby severe autism is defined by CARS
score .36, without requiring coexistent aggressive behavior.
Specifically, our past study demonstrated that sAPPa levels were
significantly increased in patients with severe autism and
aggression relative to controls and mild-to-moderate autism. Our
current study replicated this finding in a larger, independent
cohort and, importantly, found the trend to maintain significance
without the requirement for coexistent behavioral aggression. The
implication is that elevated peripheral sAPPa is a general finding
across the population of severely autistic patients. We also
analyzed levels of various amyloidogenic products of the APP
pathway. The finding that the major products of amyloidogenic
processing (Ab1-40, Ab1-42, and sAPPb) are all decreased in
severely autistic patients lends credence to the idea that the non-
amyloidogenic pathway is favored in severely autistic patients.
Some minor discrepancies between the previous and current
studies exist and are described below. First, total sAPP plasma
Figure 4. Plasma Ab levels normalized to sAPPa. To better characterize the balance between amyloidogenic and non-amyloidogenic pathways
in autism, ratios of (A) Ab1-40:sAPPa and (B) Ab1-42:sAPPa were calculated for each patient. Both ratios were significantly reduced following ANOVA
and post-hoc Dunnett’s multiple comparison test. *p=0.003, +p=0.012.
doi:10.1371/journal.pone.0020405.g004
Figure 5. Plasma levels of BDNF in control and autistic patients. BDNF levels were quantified by ELISA in plasma samples from control and
autistic patients. Absolute quantities were normalized against plasma protein concentrations. (A) Mean BDNF levels are significantly reduced in
severely autistic patients compared to controls when adjusting age as a covariate and following post-hoc Sidak’s adjustment for multiple
comparisons. (B) Estimated marginal means for plasma BDNF levels were computed with the age covariate held at 86.18 months. The mean
difference between control and severely autistic patients is enhanced when age is regressed (*p=0.038). Thus, BDNF levels are decreased in the
plasma of severely autistic patients relative to controls.
doi:10.1371/journal.pone.0020405.g005
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product of APP (sAPPa) species and were elevated in severe autism
with aggression in the original study. The current study did not
demonstrate any significant difference between levels of total sAPP
in plasma of autistic and control samples. One potential
explanation is that the Western immunoblotting technique used
to assay total sAPP levels in this study is only semi-quantitative and
may not be sensitive enough to detect subtle differences in total
sAPP between severely autistic and control patients. Second, the
degree by which sAPPa was increased in the original study was
much greater than in the current study. One possible explanation
for this discrepancy is that, as mentioned, the criterion for
inclusion into the severe autism group was less stringent for the
present study as compared to the original. It is possible that plasma
levels of sAPPa are increased more significantly in subgroups of
autistic patients with more homogenous behavioral phenotypes
and/or genotypes. The development of sophisticated classification
schemes that cluster patients into groups with more phenotypic
homogeneity or provide phenotype factors that approximate
continuous variables for covariate analysis would likely identify
larger biological differences in the levels of plasma sAPPa between
groups. Such methods based on individual ADI-R items have been
suggested [46,47] and could be incorporated into future study
designs. Third, the original study did not detect the decrease in
plasma levels of Ab1-40 or Ab1-42, which were detected in the
current study. However, in the original study, a trend towards
decreased levels of both Ab species was noticed despite not
reaching statistical significance. The enhanced power of the
current study likely enabled the true differences in Ab peptide
levels between severely autistic and control patients to attain
significance.
As mentioned, the strength of the current study is in the
increased power. Our previous study included 10 control and 10
autistic patient samples (3 severe with aggression and 7 mild-to-
moderate). Here we include for analysis 18 control, 6 mild-to-
moderate, and 15 severely autistic patient plasma samples. While
the power of the mild-to-moderate analyses is still low and may
explain why no differences were observed compared to controls,
the power associated with control versus severe autism analyses is
greatly enhanced.
Analyses from two independent laboratories have recently
confirmed a portion of these findings [48,49]. The first study
demonstrated increased plasma sAPPa levels in a large sample of
autistic patients relative to controls without requiring separate
analysis by autism severity level. This lends further credence to our
conclusion that sAPPa levels are significantly increased in the
plasma of severely autistic patients. Whether this increase
represents a generalized finding in autism or is restricted to a
more homogeneous subgroup of autistic patients sharing a
common disorder etiology is still not clear.
Autism appears to be characterized by a state of excess brain
growth in some patients, as evidenced by the widely replicated
finding of macrocephaly (i.e. enlarged head circumference) in 15-
30% of autistic patients and up to 90% in some studies
[9,10,12,50]. This volumetric deviance tends to initiate around
12 months of age and continues until middle childhood after
which point some patients may have smaller than average brain
volumes [11,50]. Some studies suggest an increase in the relative
proportion of white matter to grey matter and cerebellar
abnormalities [9,10]. Further, a decrease in the size of corpus
callosum suggests that disruptions in interhemispheric connections
may exist [51]. These findings suggest that an excess of short, local
circuit connections in an environment of general brain overgrowth
may be favored in autism [52]. Importantly, amyloid plaque found
in AD does not appear to be a component of the neuropatholog-
ical description of autism [53]. Given that processing of full-length
APP to sAPPa precludes the generation of Ab, we would not
expect that elevated sAPPa in autism would presage future plaque
deposition. This is further supported by the decreased levels of
both forms of Ab peptide levels in the plasma of severely autistic
patients tested here.
The biological activity of the secreted metabolite of APP is well-
established. The first recognized biological effect of sAPP was its
requirement for the normal proliferation of fibroblasts in culture
[54] in addition to the promotion of neuronal PC12 cell adhesion
to culture substratum [55]. Studies on cultured neurons and
animals quickly followed and have since identified trophic effects
that include the: 1) enhancement of neurite outgrowth
[56,57,58,59,60,61], 2) stimulation of neural stem cell proliferation
[62,63,64], differentiation and migration [65], 3) promotion of
synaptogenesis [66,67,68], and 4) modulation of synaptic plastic-
ity, learning and memory [69,70]. Additionally, sAPP has been
demonstrated to protect neurons against a variety of insults that
include glucose deprivation and excitotoxicity, Ab and reactive
oxygen species, and ischemic brain injury [71,72,73]. Following
the discovery of multiple secretase activities [74,75], sAPPa was
found to mediate the majority of neuronal-enhancing effects.
Specifically, the neuroprotective action of sAPPa against glucose
deprivation, excitotoxicity, and Ab toxicity is 100-fold greater than
that mediated by sAPPb [76]. The effects of excess sAPPa are
unknown and only beginning to be studied. Recently, Conti et al.
[77] found plasma sAPPa higher in a small sample of adults with
Down’s syndrome compared to both intellectually disabled and
control subjects. Autism has been associated with 10% of children
with Down’s syndrome.
Based on the data from our past and current work, we
hypothesize that the elevated levels of peripheral sAPPa observed
in severe autism is an indicant of metabolic imbalance in the CNS
– specifically an anabolic state driven by high levels of sAPPa and
perhaps other neurotrophic factors (other than BDNF) in the
brains of these patients. In our hypothesis, this state of anabolic
excess is likely to contribute to the biological substrate of the
disorder. Given the wide array of neurotrophic effects, we predict
that excessive levels of sAPPa in the brains of severely autistic
patients would induce neurodevelopmental changes that mimic
the volumetric and neuropathological changes observed in autism
[11]. What may underlie the increase in sAPPa in autism? A
decrease in beta-secretase processing is the most likely possibility,
supported by the decrease in levels of sAPPb and both Ab1-40 and
Ab1-42 peptides observed in this study. An increase in alpha-
secretase processing is a second, not mutually-exclusive, possibility.
We also cannot rule out changes to holo-APP expression. In this
context, mGluR5-dependent signaling may contribute. A mech-
anism for mGluR5-dependent translation of APP recently has
been described [78]. In this pathway, translation of APP mRNA is
constitutively inhibited by binding of (Fragile X mental retardation
protein) FMRP to the mRNA. FMRP is a RNA-binding protein
that represses translation of targeted mRNA transcripts, including
APP [78], locally within dendrites [79] and in an activity-
dependent manner. A proposed mechanism underlying repression
of APP translation by FMRP involves recruitment of CYFIP1, a
FMRP-binding partner, to the APP transcript. CYFIP1 then binds
to eIF4E and inhibits its interactions with other binding partners of
the translation initiation complex [80]. Following activation of
mGluR5 receptors, FMRP dissociates from the APP mRNA and
translation proceeds. Interestingly, excessive mGluR5 signaling
events (due to absence of FMRP) have been described in Fragile X
syndrome, a syndrome with high prevalence of co-morbid autism
Secreted Amyloid Precursor Protein-a in Autism
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to reverse the behavioral deficits in FMRP-KO mice [83,84]. If
mGluR5 signaling is enhanced in severely autistic patients,
excessive APP translation would be expected, inevitably leading
to higher sAPPa levels. Simple mGluR5 antagonism would be
expected to reverse this effect.
A separate candidate neurotrophin shown to be dysregulated in
the blood and serum of autistic patients is BDNF. The original
report on peripheral BDNF levels found a significant increase in
archived neonatal dried blood samples from autistic patients
relative to controls [16]. This led to the hypothesis that elevated
BDNF in the CNS may contribute to brain overgrowth observed
in autism [85]. Specifically, an early pre-or postnatal rise in BDNF
may herald eventual brain overgrowth while other factors may
support overgrowth at later ages. Follow-up studies, including
some from independent labs have either demonstrated a similar
increase in peripheral BDNF with autism [14,15,86], found no
association with autism [87], or demonstrated reduced peripheral
BDNF levels with autism [88,89] , as found in this report. The
discrepancy between studies likely arises from differences in
sample types analyzed, assay methods used, repeated freeze-thaw
cycles and age of patients when samples were collected. In
typically developing individuals, peripheral BDNF levels have
been found to rise rapidly with age [14], and then decrease into
adulthood [89]. Consequently, due to the anticipated effect of age
on BDNF, and because of a somewhat high variation of age in our
tested samples, we utilized patient age as a covariate when
analyzing BDNF levels. Using the ANCOVA model, we observed
a significant decrease in the levels of plasma BDNF in severely
autistic patients relative to controls. If peripheral BDNF levels
correlate well with brain BDNF levels as has been suggested [90],
our finding of decreased plasma BDNF would suggest that BDNF
alone cannot account for brain overgrowth in autism. Indeed, a
recent study has found decreased BDNF levels in the brains of
autistic patients as compared to controls and has suggested this
may lead to reduced BDNF-Akt-Bcl2 anti-apoptotic signaling in
autism [91]. This finding lends further credence to the idea that
sAPPa or other neurotrophic factors must contribute to this
phenotype. At the neuronal and synapse level, it is noteworthy that
BDNF-p75NTR-dependent signaling appears to promote devel-
opmental axon pruning through axon degeneration [92]. A CNS
environment of excess sAPPa and reduced BDNF might be
expected to promote neuronal proliferation, differentiation, and
synaptogenesis along with a deficit in axon pruning, leading to a
state of general brain overgrowth.
Neurobiologically, the contrasts between neurodegenerative
conditions (such as Alzheimer’s and some forms of schizophrenia)
and conditions involving overgrowth/overactivity of growth
pathways (such as FXS and autism) are quite intriguing and our
recent work has addressed the molecular-pathway underpinnings
of such contrasts (Sokol et al, 2011). The present work should lay
the path for further research beyond autism. For example, it is not
clear whether the sAPPa-mediated brain overgrowth pathway
described herein is applicable to autism only or can be extended to
other psychiatric disorders with either brain overgrowth or
undergrowth. Autism-spectrum and psychotic-spectrum condi-
tions (i.e. schizophrenia, bipolar disorder, and major depression)
represent two major suites of disorders of human cognition and
behavior with altered development and function of the social brain
[93], Should one then expect sAPPa to follow different trajectories
in these conditions? What about the gender bias in autism, where
the prevalence in boys is 1 in 70, as opposed to 1 in 110 for all
children? Could this be explained by ‘‘genomic conflict’’ during
brain development [94], or is it due to some unknown
environmental or epigenetic factors? [95]. Future studies will need
to carefully investigate levels of sAPPa, BDNF and other protein
markers in samples from different genders and other psychiatric
conditions to answer some of these questions.
In summary, we have confirmed the finding from our original
report of increased sAPPa in the plasma of severely autistic
patients. We have also found that this elevation is not limited to
only severely autistic patients exhibiting aggressive behaviors.
Further, we demonstrate for the first time that Ab1-40, Ab1-42
and sAPPb levels are reduced in the plasma of severely autistic
patients. These biochemical changes may be characteristic of a
subgroup of patients with a more homogenous phenotype and as
such could be a useful biomarker to track in future studies or
perhaps for inclusion in a future diagnostic panel of biomarkers.
Furthermore, we predict that the peripheral elevation of sAPPa is
indicative of high CNS sAPPa levels and that this contributes to an
anabolic state that underlies macrocephaly, brain overgrowth and
other neurodevelopmental abnormalities in autism. Given that the
highest rate of brain overgrowth in autism appears to occur in the
first few years of life [50], measurement of peripheral sAPPa levels
during this time of development could reveal even greater
differences between severely affected patients and controls, and
serve as a marker of autism severity. It must be stressed that it is
presently unknown if the change in peripheral sAPPa is mirrored
in the brain of severely autistic patients. These samples are difficult
to obtain due to low age of the required control and affected
patients. Nevertheless, future studies are required to address this
caveat. Taken together, this research should have a significant
impact, not only in clarifying the etiology of autism and related
neurodevelopmental disorders, but also in guiding future research
on the sAPP and mGluR pathways at the cellular level and as
putative therapeutic drug targets.
Materials and Methods
Ethics statement
This study was approved by the Indiana University School of
Medicine Institutional Review Board’s Human Subjects Commit-
tee (IUPUI campus, Indianapolis, IN, USA). All parents signed
informed consent for their child’s participation. Additionally, all
research was conducted according to the principles expressed in
the Declaration of Helsinki.
Participants, diagnostic inclusion criteria, and measures
The inclusion criteria for the autism group were a diagnosis of
Autistic Disorder based on the DSM-IV criteria determined by an
experienced neurologist (DKS), which was further corroborated by
the Autism Diagnostic Interview-Revised (ADI-R) [37]. The ADI-
R is a comprehensive, semi-structured parent interview that
assesses a child’s developmental history and relevant behaviors
characteristic of autism and generates a diagnostic algorithm for
Autistic Disorder. Children with genetic causes of autism, e.g.,
Fragile X syndrome, were excluded. Typically developing age-
and gender-matched volunteers comprised the control group.
These children had no major medical problems, were on no
medication, and had met their developmental milestones and/or
were functioning in typically developing classrooms. The Child-
hood Autism Rating Scale (CARS) [38] was obtained for all
participants. This parent questionnaire is a 15-item behavioral
rating scale developed as a screen for autism and to classify
severity. Validity and reliability for the CARS have been
established [38]. Participants were administered age appropriate
cognitive testing (i.e., Mullens Scales of Early Learning [39] or
Wechsler Intelligence Scale for Children-IV [40]).
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A. Removal of albumin from human plasma. For some
antibody-dependent assays described below, the levels of highly
abundant proteins present in plasma samples interfered with assay
sensitivity, specificity and/or linearity due to non-specific protein
interactions. To circumvent these issues, aliquots of raw plasma
samples were pre-fractionated by depletion of the majority of
human plasma albumin using ProteomeLab IgY human serum
albumin (HSA) spin column-based proteome partitioning kit
(Phenomenex, Torrance, CA). Briefly, plasma samples were pre-
filtered using Corning Costar Spin-X 0.45 mm cellulose acetate
filters, diluted 25-fold using kit-supplied 1x dilution buffer, and
then incubated with anti-HSA-coated beads for 15 minutes.
Albumin-depleted plasma was collected as flow-through.
Preliminary SDS-PAGE experiments utilizing flow-through,
wash and eluate fractions demonstrated that a large majority of
albumin was successfully removed by this procedure (data not
shown). These diluted, albumin-immunosubtracted samples were
then used directly without further concentration for biochemical
analyses as indicated. Concentration was not performed in order
to avoid variation in the final volume of HSA-immunosubtracted
plasma obtained after concentration.
B. Measurement of total protein content in the
plasma. Two microliters of raw plasma were diluted ten-fold
with freshly prepared Dulbecco’s phosphate buffered saline
(DPBS) and measurement of total protein content in the plasma
was performed using Bradford protein assay method as described
previously [41]. Total protein content of all HSA-
immunosubtracted plasma samples was also determined using
the Bradford method.
C. Levels of total sAPP by Western immunoblot
assay. To avoid non-specific binding of antibody with
abundant HSA in raw plasma, we used HSA-immunosubtracted
plasma when assaying levels of total sAPP by Western
immunoblotting. Briefly, equal volume of denatured HSA-
immunosubtracted plasma was loaded on two 26-lane Bis-Tris
Criterion XT gels (BioRad) and electrophoresis was carried out for
1 hour at 180 V and the proteins from the gels were
electrophoretically transferred onto a PVDF membrane and
blocked in 5% non-fat milk as previously described [42]. After
blocking, the membrane was probed with monoclonal anti-APP
antibody (Clone 22C11, Millipore, MA, USA), which recognizes
the 66-81 amino acid sequence of APP (N-terminus). This epitope
is present in all sAPP forms (such as sAPPa, sAPPb and sAPP c)
and their post-translational modifications and, thus, allows
detection of the total sAPP pool. After incubation with HRP-
conjugated anti-mouse secondary IgG, blot signals were obtained
using the ECL method. Band densities were quantified using
Image J software [43] and densities were normalized to total
protein content of HSA-immunosubtracted plasma.
D. Levels of sAPPa by ELISA. For all ELISAs, we
performed initial experiments with different volumes of plasma
samples to establish linearity of the assays. Equal volumes of HSA-
immunosubtracted plasma were used to assay the levels of sAPPa
by the sandwich ELISA method (Immuno-Biological Laboratories,
Gumma, Japan or IBL). Briefly, an equal volume (50 ml) of HSA-
immunosubtracted plasma was added onto wells pre-coated with
capture monoclonal anti-human sAPPa antibody (clone 2B3) and
incubated overnight at 4uC. After washing several times, the wells
were incubated with HRP-conjugated monoclonal anti-APP
detection antibody (clone 10D1). Colorimetric signals were
obtained after addition of chromogen substrate followed by
application of 1N sulfuric acid. A standard curve was prepared
by using known amounts of recombinant human sAPPa protein.
sAPPa values (ng/ml) in all HSA-immunosubtracted plasma
samples were normalized to total protein content of HSA-
immunosubtracted plasma.
E. Levels of sAPPb by ELISA. We have measured the levels
of sAPPb by a commercially available ELISA kit (IBL) as per the
manufacturer’s protocol. Briefly, 50 ml of HSA-immunosubtracted
plasma from each control and autism subject was separately
loaded onto a prelabeled well of a 96-well ELISA plate and
allowed to incubate overnight at 4uC with pre-coated anti-human
sAPPb wild type antibody, which recognizes C-terminus of human
sAPPb. After several washes, the wells were incubated with HRP-
conjugated anti-APP detection antibody (10D1). Colorimetric
signals were obtained in the same way as mentioned in the section
of sAPPa ELISA. A series of known amounts of human
recombinant sAPPb samples were likewise incubated and
processed to prepare a standard curve. Similar to other ELISAs
used in this report, sAPPb values were normalized by the total
protein content of HSA-immunosubtracted plasma.
F. Levels of Ab1-40 peptide by specific ELISA. Ab1-40
levels were measured using an Ab-40-specific sandwich ELISA kit
(Biosource, MN, USA) as described previously [44]. Wells were
pre-coated with monoclonal antibody specific for the N-terminal
amino acid sequence of human Ab peptide. Equal volumes of raw
plasma samples mixed with detection antibody (rabbit polyclonal
antibody specific for C-terminus of human Ab1-40) were
incubated at room temperature for three hours. Colorimetric
signals were obtained in a similar fashion to other ELISAs [44]. A
standard curve using known amounts of Ab1-40 was also
performed and plasma Ab1-40 values (pg/ml) were normalized
to total protein content of raw plasma samples.
G. Levels of Ab 1–42 peptide by specific ELISA. Ab1-42
levels were measured using an Ab-42-specific ELISA kit
(Biosource, MN, USA). Wells were pre-coated with monoclonal
anti-Ab antibody which is specific to the N-terminal sequence of
human Ab peptide. The detection antibody was specific for the C-
terminal sequence of human Ab1-42 peptide. The assay was
performed as per the manufacturer’s guideline. Levels of Ab1-42
in the plasma were calculated from a standard curve prepared
using known amounts of human Ab1-42 peptide and normalized
to the total protein content of raw plasma samples. Ratios of Ab1-
40 and Ab1-42 were calculated from total protein content-
normalized values.
H. Measurement of BDNF in plasma by ELISA. For
BDNF assay, equal volume of platelet-free raw plasma was loaded
into a plate pre-coated with mouse monoclonal anti-BDNF
antibody (R & D Systems, MN, USA) and incubated at room
temperature for two hours. HRP-conjugated monoclonal anti-
BDNF detection antibody was added to the wells and further
incubated for one hour. After brief wash, substrate solution was
applied to the wells and incubated for 30 minutes. The reaction
was stopped by application of Stop Solution (2N sulfuric acid). The
colorimetric signals were measured using a microplate reader
(BioRad, CA, USA). A standard curve with known amounts of
recombinant human BDNF was also performed to calculate
absolute quantities of BDNF present in each plasma sample. This
BDNF value was normalized to the total protein content of each
plasma sample, as measured by the Bradford method.
Data Analysis
All statistical analyses were performed using SPSS Statistics 17.0
software and all plots were constructed using GraphPad Prism 4.0
software. Unless otherwise stated, all data are presented as mean
6 SEM. Further, ANOVA or ANCOVA analyses were performed
where indicated under the framework of the general linear model.
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nett’s t-test or Sidak’s multiple comparison test, as indicated. The
a threshold was set to 0.05 for determining statistical significance
in all cases.
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